CorMedix, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its primary focus is on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix, Inc. was founded in 2006 and is based in Berkeley Heights, New Jersey.
Industry, Sector and Symbol
Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolNYSEAMERICAN:CRMD
CUSIPN/A
Phone+1-908-5179500
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-16,300.49%
Return on Equity-318.95%
Return on Assets-227.65%
Miscellaneous
EmployeesN/A
Outstanding Shares81,900,000
Market Cap$18.50 million
CorMedix (NYSEAMERICAN:CRMD) Frequently Asked Questions
What is CorMedix's stock symbol?
CorMedix trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CRMD."
How were CorMedix's earnings last quarter?
CorMedix Inc. (NYSEAMERICAN:CRMD) announced its quarterly earnings results on Tuesday, August, 14th. The biotechnology company reported ($0.10) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.10). The biotechnology company earned $0.01 million during the quarter, compared to analysts' expectations of $0.10 million. CorMedix had a negative return on equity of 318.95% and a negative net margin of 16,300.49%. View CorMedix's Earnings History.
When is CorMedix's next earnings date?
What price target have analysts set for CRMD?
1 brokerages have issued twelve-month target prices for CorMedix's stock. Their forecasts range from $3.00 to $3.00. On average, they anticipate CorMedix's stock price to reach $3.00 in the next year. This suggests a possible upside of 538.3% from the stock's current price. View Analyst Price Targets for CorMedix.
What is the consensus analysts' recommendation for CorMedix?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CorMedix in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CorMedix.
Are investors shorting CorMedix?
CorMedix saw a increase in short interest in the month of July. As of July 31st, there was short interest totalling 8,290,561 shares, an increase of 27.2% from the July 13th total of 6,519,232 shares. Based on an average daily trading volume, of 7,874,307 shares, the days-to-cover ratio is presently 1.1 days. Currently, 10.7% of the shares of the company are short sold. View CorMedix's Current Options Chain.
Who are some of CorMedix's key competitors?
Some companies that are related to CorMedix include GB Sciences (GBLX), OncoCyte (OCX), InMed Pharmaceuticals (IMLFF), Navidea Biopharmaceuticals (NAVB), Botanix Pharmaceuticals (BOT), IntelGenx Technologies (IGX), BELLUS Health (BLU), Medicenna Therapeutics (MDNA), Destiny Pharma (DEST), NovaBay Pharmaceuticals (NBY), Rexahn Pharmaceuticals (RNN), Abzena (ABZA), OptiBiotix Health (OPTI), Scancell (SCLP) and Synthetic Biologics (SYN).
Who are CorMedix's key executives?
CorMedix's management team includes the folowing people:
- Mr. Khoso Baluch, CEO & Director (Age 60)
- Mr. Robert W. Cook, Chief Financial Officer (Age 62)
- Mr. John L. Armstrong Jr., Head of HR & Exec. VP of Technical Operations (Age 74)
- Ms. Elizabeth Masson, Exec. VP & Head of Clinical Operations
- Mr. John Ortiz, VP of Regulatory Affairs & Quality Assurance
Has CorMedix been receiving favorable news coverage?
News stories about CRMD stock have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm identifies positive and negative news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. CorMedix earned a media and rumor sentiment score of 0.10 on Accern's scale. They also assigned headlines about the biotechnology company an impact score of 47.42 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days. View Recent Headlines for CorMedix.
How do I buy shares of CorMedix?
Shares of CRMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is CorMedix's stock price today?
One share of CRMD stock can currently be purchased for approximately $0.47.
How big of a company is CorMedix?
CorMedix has a market capitalization of $18.50 million.
How can I contact CorMedix?
CorMedix's mailing address is 1430 US Highway 206 Ste 200, BEDMINSTER, NJ 07921-4602, United States. The biotechnology company can be reached via phone at +1-908-5179500.
MarketBeat Community Rating for CorMedix (NYSEAMERICAN CRMD)
MarketBeat's community ratings are surveys of what our community members think about CorMedix and other stocks. Vote "Outperform" if you believe CRMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
